Biogen Inc. (BIIB) Stock Price, Quote & News

AI Score

Unlock

AI Score

Our AI model analyzes fundamental, technical, and statistical indicators to predict the probability of a bullish trend over the next three months.

We regularly update and refine our models to deliver the most reliable forecasts for you.

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

Biogen Inc. (BIIB)

AI Score

Unlock

AI Score

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

143.00

-7.18 (-4.78%)

At close: Jan 14, 2025, 8:58 PM

143.08

0.05%

After-hours Jan 14, 2025, 07:00 PM EST

undefined% (undefined)

Bid	143
Market Cap	20.84B
Revenue (ttm)	-
Net Income (ttm)	-
EPS (ttm)	11.05
PE Ratio (ttm)	12.94
Forward PE	n/a
Analyst	Hold

Ask	143.33
Volume	1,390,315
Avg. Volume (20D)	1,498,347
Open	149.92
Previous Close	150.18
Day's Range	142.42 - 150.22
52-Week Range	142.42 - 252.17
Beta	undefined

About BIIB

Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an etanercept biosimilar referencing ENBREL; ADUHELM for the treatment of Alzheimer's disease; IMRALDI, an ad...

[Show more]

Industry Drug Manufacturers - General

Sector Healthcare

IPO Date Sep 17, 1991

Employees 7,570

Stock Exchange NASDAQ

Ticker Symbol BIIB

Website https://www.biogen.com

Analyst Forecast

According to 25 analyst ratings, the average rating for BIIB stock is "Hold." The 12-month stock price forecast is $210, which is an increase of 46.85% from the latest price.

Buy 44.00%

Hold 52.00%

Sell 0.00%

Stock Forecasts

Next Earnings Release

Biogen Inc. is scheduled to release its earnings on Feb 11, 2025, before market opens.
Analysts project revenue of $2.42B, reflecting a 1.42% YoY growth and earnings per share of 3.44, making a 16.61% increase YoY.

Why Price Moved

1 month ago · Source

-1.28%

Biogen shares are trading lower after Needham down... Unlock content with Pro Subscription

5 months ago · Source

-3.53%

Biogen shares are trading lower after Needham and Truist Securities lowered their respective price targets on the stock.

News

1 day ago · reuters.com

Biogen CEO sees no burning need for more acquisitions

Biogen expects revenue from new launches to exceed its current sales by 2028 and does not feel the need to chase additional business development deals, the company's CEO said.

1 day ago · zacks.com

Biogen Offers to Buy Remaining Stake in Sage Therapeutics

Biogen offers to buy the remaining stake in Sage Therapeutics for $7.22 per share. SAGE stock rises.

2 days ago · proactiveinvestors.com

Sage Therapeutics shares surge on unsolicited takeover bid from Biogen

Sage Therapeutics (NASDAQ:SAGE) stock soared after the firm announced that it had received an unsolicited takeover bid from Biogen Inc (NASDAQ:BIIB, ETR:IDP). Biogen has proposed to acquire all of Sag...

2 days ago · https://thefly.com

Sage takeout bid implies zero enterprise value, says Mizuho

Sage Therapeutics + Biogen -0.36 (-0.24%)

2 days ago · https://thefly.com

Biogen bid for Sage does not change narrative, says BMO Capital

Biogen -1.98 (-1.31%) Sage Therapeutics -0.29 (-4.96%)

2 days ago · https://thefly.com

Sage Therapeutics takeover bid undervalues Zurzuvae, says Truist

Sage Therapeutics -0.29 (-4.96%) Biogen -1.98 (-1.31%)

2 days ago · https://thefly.com

BofA moves to No Rating on Sage Therapeutics after Biogen bid

Sage Therapeutics -0.29 (-4.96%) Biogen -1.98 (-1.31%)

2 days ago · barrons.com

Sage Therapeutics Stock Rockets 35% Higher After Takeover Bid From Biogen

The biopharmaceutical company says its board of directors will now review and evaluate the offer from Biogen.

5 days ago · businesswire.com

Sage Therapeutics Confirms Receipt of Unsolicited Nonbinding Acquisition Proposal from Biogen

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sage Therapeutics, Inc. (Nasdaq: SAGE) (“The Company”), today confirmed that Biogen Inc. (Nasdaq: BIIB) (“Biogen”) has submitted to the Company an unsolicited, nonbi...

5 days ago · reuters.com

Biogen proposes to buy remaining stake in Sage in $442 million deal

Drugmaker Biogen will buy all outstanding shares of Sage Therapeutics that it does not already own for $7.22 apiece, a filing showed on Friday, sending the latter's stock up 34% in extended trade.

1 week ago · businesswire.com

Cardurion Pharmaceuticals Appoints Charlotte Newman as Chief Business Officer

BURLINGTON, Mass.--(BUSINESS WIRE)--Cardurion Pharmaceuticals, Inc. (“Cardurion”), a clinical-stage biotechnology company discovering and developing new therapeutic approaches for the treatment of car...

1 week ago · fool.com

These Were the 5 Worst-Performing Stocks in the Nasdaq-100 in 2024

Now that we've shut the door on 2024, it's useful to look back at some of the best -- and, on the flip side, some of the worst -- performers of the year on the stock market. Many outliers were in the ...

2 weeks ago · zacks.com

Why Biogen Inc. (BIIB) is a Top Value Stock for the Long-Term

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

2 weeks ago · seekingalpha.com

Beaten Down Biogen Stock Looks Attractive At Current Levels

The Biogen Inc. story of the last 10 years has been one of periods of excitement, followed by significant disappointments. The company is executing a turnaround strategy that includes cost-cutting, pi...

3 weeks ago · youtube.com

Pharma has value names, but it's not a top pick for 2025, says BMO's Evan Siegerman

Evan Siegerman, BMO biotech analyst, joins 'Power Lunch' to discuss the big winners in the pharmaceutical space in 2025.

1 month ago · reuters.com

Private Medicare plans must cover Biogen's ALS drug, US agency says

The Centers for Medicare & Medicaid Services has directed private insurers providing Medicare Advantage plans to cover Biogen's amyotrophic lateral sclerosis drug Qalsody after finding instances of co...

1 month ago · investors.com

Analysts Predict These Will Be Next Year's Top 10 Stocks

Missed out on this year's top S&P 500 stocks? Analysts are already offering up their ideas on which stocks will rule in 2025.

1 month ago · zacks.com

Biogen Stock Declines 21.4% in 3 Months: How to Play the Stock

Though there is uncertainty about Biogen's sales and profits improving significantly, investors can hold the stock given the potential of its new drugs.

1 month ago · benzinga.com

Biogen Downgraded On Pipeline Setbacks And Leqembi Sales Slowdown

Jefferies downgraded Biogen Inc BIIB, citing the company's tough setup.

1 month ago · seekingalpha.com

Biogen Inc. (BIIB) Presents at 7th Annual Evercore ISI HealthCONx Healthcare Conference Call Transcript

Biogen Inc. (NASDAQ:BIIB ) 7th Annual Evercore ISI HealthCONx Healthcare Conference Call December 3, 2024 9:10 AM ET Company Participants Alisha Alaimo - President and Head of North America Michael Mc...

Load More News